[Established and atypical neuroleptics. What the family physician should know]

Some 30-50% of schizophrenic patients fail to respond at all, or only inadequately, to the classical neuroleptics. The side effects profile is broad--in particular adverse reactions affecting the extrapyramidal motor system may be induced. In recent years, numerous, so-called atypical neuroleptic agents have been approved. These substances are characterized by improved efficacy and fewer side effects. The downside, however, is that they are considerably more expensive than the established neuroleptics. A further disadvantage is the fact that no depot preparations are as yet available. Finally, some of these substances lead to a marked increase in weight.